Healthy Living

New Muscular Dystrophy Drug Granted FDA Orphan Designation in US

Hope for OPMD

While there is no cure for OPMD, unlike so many other rare diseases out there, there is hope that a treatment option will soon be available to anyone who needs it. Thanks to getting the orphan drug designation, development of BB-301 will continue with full force and will hopefully hit the market soon.  On average, newly developed drugs can take up to 10 years before they hit the market - that’s how long the usual full development process takes. The orphan drug designation not only helps the company deal with the financial burden of getting those drugs to those who need them, it also allows them to do it much faster. Orphan drugs play a huge role in helping those who suffer from rare diseases, that’s why it’s so important for that kind of development work to continue.